Mutual funds are subject to market risk. Read all scheme documents carefully.
This fund is not currently rated by our system. However, we continuously review and update our ratings, so it may be included in the future.
Our score weighs long-term performance, risk and consistency — not just past returns.
As of 13 Nov 2026
Long Term Wealth Creation, An open ended equity scheme following contrarian investment strategy
The scheme seeks to generate long-term capital appreciation by investing in Equity & Equity related instruments following contrarian investment strategy.
Exit load of 1%, if redeemed within 1 month.

As of 31 Oct 2026
| Holding | % of fund | Value | Shares |
|---|---|---|---|
| HDFC Bank Ltd. | 9.36% | ₹148.16 Cr | 21,38,540 |
| Natco Pharma Ltd. | 6.59% | ₹104.32 Cr | 13,33,333 |
| Britannia Industries Ltd. | 4.88% | ₹77.16 Cr | 1,66,303 |
| Avenue Supermarts Ltd. | 4.67% | ₹73.95 Cr | 2,31,170 |
| Medplus Health Services Ltd. | 4.61% | ₹72.97 Cr | 12,58,358 |
| Shree Cement Ltd. | 4.35% | ₹68.91 Cr | 29,967 |
| Bajaj Finserv Ltd. | 4.21% | ₹66.59 Cr | 3,99,326 |
| Tata Motors Passenger Vehicles Ltd. | 4.12% | ₹65.19 Cr | 24,56,282 |
| Pidilite Industries Ltd. | 3.84% | ₹60.84 Cr | 4,16,228 |
| ITC Ltd. | 3.34% | ₹52.83 Cr | 19,89,225 |